Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05162443 |
Expanded Access Status :
Approved for marketing
First Posted : December 17, 2021
Last Update Posted : May 19, 2023
|
- Study Details
- Tabular View
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Advanced Cancer Metastatic Cancer Malignant Neoplasm | Drug: adagrasib (MRTX849) |
Study Type : | Expanded Access |
Expanded Access Type : | Intermediate-size Population |
See clinical trials of the intervention/treatment in this expanded access record. | |
Official Title: | Expanded Access Use of Adagrasib (MRTX849) for the Treatment of Patients With Advanced Solid Tumors With a KRAS G12C Mutation |
- Drug: adagrasib (MRTX849)
adagrasib (MRTX849) will be administered orally twice daily in a continuous regimen
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Inclusion Criteria:
- Histologically or cytologically confirmed diagnosis of an advanced/metastatic solid tumor
- Confirmed presence of a KRASG12C mutation
- Ineligible for an ongoing clinical trial of MRTX849
- No available or not eligible for standard of care treatment
- Adequate organ function
- CNS Metastases (within set parameters) are allowed
- ECOG performance status of ≤ 2
Exclusion Criteria:
- History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter absorption of MRTX849 treatment or result in inability to swallow
- Prior therapy targeting a KRAS G12C mutation
- Other active cancer
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05162443
United States, California | |
California Pacific Medical Center | |
San Francisco, California, United States, 94115 | |
Providence Medical Group Santa Rosa - Cancer Center | |
Santa Rosa, California, United States, 95403 | |
United States, Connecticut | |
Hartford Hospital | |
Hartford, Connecticut, United States, 06106 | |
United States, Georgia | |
Piedmont Cancer Institute | |
Atlanta, Georgia, United States, 30318 | |
United States, Minnesota | |
Mayo Clinic - Rochester | |
Rochester, Minnesota, United States, 55905 | |
United States, Nevada | |
Renown Health | |
Reno, Nevada, United States, 89502 | |
United States, Pennsylvania | |
Lehigh Valley Cancer Institute | |
Allentown, Pennsylvania, United States, 18103 | |
United States, Texas | |
Lumi Research | |
Kingwood, Texas, United States, 77339 | |
United States, Virginia | |
Virginia Cancer Institute | |
Richmond, Virginia, United States, 23230 | |
United States, Washington | |
Seattle Integrative Cancer Center | |
Renton, Washington, United States, 98057 | |
Swedish Cancer Institute | |
Seattle, Washington, United States, 98104 |
Responsible Party: | Mirati Therapeutics Inc. |
ClinicalTrials.gov Identifier: | NCT05162443 |
Other Study ID Numbers: |
849-EAP-001 |
First Posted: | December 17, 2021 Key Record Dates |
Last Update Posted: | May 19, 2023 |
Last Verified: | May 2023 |
adagrasib expanded access |
Neoplasms Adagrasib Antineoplastic Agents |